Biomimetic Scaffolds for Peripheral Nerve Repair

Abstract

Peripheral nerve injuries represent a significant clinical challenge due to their high incidence, complex pathophysiology, and often suboptimal outcomes with traditional repair techniques. Biomimetic scaffolds, inspired by the native extracellular matrix and neuroanatomical architecture, have emerged as promising tools to bridge nerve gaps, enhance regeneration, and improve functional recovery. This review provides an in-depth analysis of the current state of biomimetic scaffold technologies for peripheral nerve repair, discussing the epidemiology, mechanisms of nerve injury, scaffold design principles, clinical evidence, advantages, limitations, and future directions, with a focus on translating benchside innovations into bedside solutions.

Introduction

Peripheral nerve injuries (PNIs) are a prevalent cause of morbidity worldwide, often resulting from traumatic incidents, surgical procedures, or disease processes. The restoration of nerve continuity and function remains a formidable challenge, particularly when nerve gaps exceed the capacity of direct end-to-end repair. Autologous nerve grafts, the historical gold standard, bear limitations such as donor site morbidity, limited tissue availability, and variable results. In recent years, biomimetic scaffolds—engineered constructs designed to emulate the physiological microenvironment of nerves—have garnered attention as alternatives capable of supporting axonal growth and functional recovery. This review synthesizes the latest evidence and clinical insights regarding the use of biomimetic scaffolds in peripheral nerve repair.

Epidemiology / Disease Burden

Peripheral nerve injuries affect approximately 13–23 per 100,000 individuals annually, with higher prevalence observed in young adults and males due to occupational and vehicular trauma. Such injuries can result in significant sensory and motor deficits, chronic pain syndromes, and long-term disability, leading to substantial socioeconomic impact. The burden is compounded by the limited regenerative capacity of adult peripheral nerves and the suboptimal outcomes associated with conventional repair methods, highlighting the urgent need for innovative therapies.

Pathophysiology

PNIs disrupt the continuity of axons and supporting Schwann cells, leading to Wallerian degeneration distal to the lesion and a complex cascade of cellular and molecular events. The regenerative process is contingent upon the alignment of severed nerve endings, preservation of endoneurial tubes, and timely reinnervation by regenerating axons. In cases of large nerve gaps, the absence of a guiding matrix impedes axonal extension, resulting in neuroma formation and poor functional outcomes. Biomimetic scaffolds are designed to recapitulate the native extracellular matrix, providing physical guidance, trophic support, and permissive cues for axonal regrowth.

Risk Factors

Risk factors for poor peripheral nerve regeneration include advanced patient age, delayed intervention, large nerve gap length (>3 cm), crush or avulsion injuries, comorbidities such as diabetes mellitus, and infection. Additionally, the anatomical location and complexity of the affected nerve, as well as the quality of surgical repair, influence the likelihood of successful regeneration. Understanding these risk factors is crucial for patient selection and the tailoring of scaffold-based interventions.

Clinical Features

Patients with peripheral nerve injuries typically present with sensory disturbances (numbness, paresthesia), motor deficits (weakness, paralysis), and, in some cases, neuropathic pain. The pattern of deficits correlates with the location, severity, and extent of the injury. High-grade injuries may manifest with complete loss of function, muscle atrophy, and trophic skin changes, underscoring the need for timely and effective repair strategies.

Diagnosis

Diagnosis of peripheral nerve injuries involves a combination of clinical assessment, electrophysiological studies (nerve conduction studies, electromyography), and imaging modalities such as magnetic resonance neurography or high-resolution ultrasound. These tools aid in the characterization of injury severity, localization of lesions, and assessment of regenerative progress. Histopathological evaluation of nerve biopsies or intraoperative assessment may be warranted in select cases, particularly for research purposes or complex clinical scenarios.

Treatment & Management

The primary goal of PNI management is to restore nerve continuity and function. For small nerve gaps (<5 mm), tensionless end-to-end neurorrhaphy is preferred. Larger gaps traditionally require autologous nerve grafts; however, these are limited by donor site morbidity and finite supply. Allografts and synthetic conduits have been utilized with mixed success. Biomimetic scaffolds, composed of natural or synthetic polymers (e.g., collagen, chitosan, polylactic-co-glycolic acid), aim to replicate the native nerve extracellular matrix, offering a biocompatible and customizable platform for axonal guidance, cellular infiltration, and controlled delivery of growth factors.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in scaffold design, including the development of multi-channel, nanofiber, and hydrogel-based constructs, as well as the incorporation of bioactive molecules (e.g., nerve growth factor, brain-derived neurotrophic factor), stem cells, and electrical stimulation capabilities. Preclinical and early-phase clinical studies demonstrate improved axonal regeneration, remyelination, and functional recovery with these advanced biomimetic scaffolds compared to conventional nerve conduits. 3D bioprinting and patient-specific scaffold fabrication are also emerging, offering personalized regenerative solutions. However, challenges remain regarding long-term biocompatibility, scalability, regulatory approval, and cost-effectiveness.

Guideline Recommendations

Current clinical guidelines endorse tensionless neurorrhaphy for small gaps and autologous nerve grafts for larger defects, with synthetic conduits or scaffolds considered in select cases where autografts are not feasible. Emerging consensus from expert panels encourages the integration of biomimetic scaffolds into clinical trials, particularly for complex or large-gap injuries, while emphasizing the need for standardized outcome measures and long-term follow-up. Ongoing research is likely to inform future guidelines as more robust clinical data become available.

Conclusion

Biomimetic scaffolds represent a transformative advance in peripheral nerve repair, offering the potential to overcome the limitations of traditional grafting techniques. By providing an engineered microenvironment conducive to axonal regeneration, these scaffolds may significantly enhance clinical outcomes for patients with challenging nerve injuries. Continued interdisciplinary research, rigorous clinical evaluation, and technological refinement are essential to fully realize the promise of biomimetic scaffolds in routine clinical practice.